Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

Class: Geographical_Location

Annotations (1)

- rdfs:comment "In this study, we examined the geographic patterns of lung cancer incidence for Philadelphia and its surrounding regions over two ten-year periods from 1998 to 2017. We identified ZIP codes with high lung cancer incidence relative to the PA state rates and located clusters or “hotspots” of high incidences. Our results demonstrated that lung cancer incidence rates were not the same across the ZIP codes in the five PA counties, suggesting disparity in environmental exposure or other risk factors. Almost all analyses suggested the southeastern study region inside Philadelphia county bordering New Jersey had higher rates of lung cancer. Local indicators of Moran’s I confirmed this general area as having clusters of significantly high incidence. These ZIP codes housed manufacturing industries in the past (some are remaining) and tracked closely along the I-95 highway. Factories and road traffic may be possible sources of hazardous exposures that can increase lung cancer risks. Although over half of the ZIP codes showed a decline in rates from 1998–2007 to 2008–2017, certain ones had high incidence across both time periods. Approximately one in four—making up 24% of those studied—ZIP codes in the study area had significantly higher incidence rates than that of the state as a whole in both time periods. Many of those ZIP codes were also identified to be in high incidence clusters with rate ratios ranging from 1.2 to 1.9. Regions with increased rates may benefit from further investigation of the reasons for the observed trend. The high incidence ZIP codes were denser in terms of population size, poorer, and had lower percentages of whites and larger Hispanic populations. We further showed that these areas were in closer proximity to a greater number of TRI facilities, which released greater amounts of toxic emissions including many carcinogenic compounds, and to a major interstate highway. Surprisingly, given the established risk posed by smoking, the average household cigarette expenditure was lower for high incidence ZIP codes. Although cigarette expenditure is not a perfect measure of smoking behavior, this result may suggest that smoking may be more reflective of individual-specific risk; thus, associations between smoking and lung cancer may not transfer from the individual level to the group level (population in a certain zip code). When considering differences in risk between subpopulations, environmental factors may be more important. The comparison of high incidence ZIP codes to others pointed out additional factors to consider, emphasizing the contribution of one’s location. People who have known risk factors (e.g., smoking history, exposure to second-hand smoking, working in occupations that expose them to potential toxicants, etc.) may be more vulnerable and have the added burden of living in these areas. Characteristics and locations of these high incidence areas also matched with those for environmental justice communities [38], which are socially and economically disadvantaged and underserved. These findings suggested that identified communities may be disproportionately vulnerable to lung cancer and may require more attention. Based on our geographic and clustering analyses of lung cancer incidence rates, we detected areas with high incidences in southeastern Pennsylvania along its border with New Jersey. These areas were associated with lower socioeconomic status and closer proximity to potential sources of pollution. Thus, environmental exposures and community risk factors corresponding to residential location may make certain individuals more susceptible to lung cancer, on top of the risk posed by smoking status. Future research is warranted to understand how risk factors identified in this study can be incorporated into existing risk assessment tools according to their relative effects on disease development and possible interactions between different factors. This may be accomplished by analyzing the significant risk factors we found in a spatial regression model. Public health professionals may use these tools to better identify individuals for targeted screening of lung cancer and greater surveillance."

Superclasses (1)

- Location_LC

Disjoints (691)

'\'Abraxane_(Paclitaxel_Albumin-stabilized_Nanoparticle_Formulation)_\'', '\'Afinitor_(Everolimus)\'', '\'Afinitor_Disperz_(Everolimus)_\'', '\'Alecensa_(Alectinib)_\'', '\'Alimta_(Pemetrexed_Disodium)_\'', '\'Alunbrig_(Brigatinib)_\'', '\'Alymsys_(Bevacizumab)_\'', '\'Avastin_(Bevacizumab)_\'', '\'Cyramza_(Ramucirumab)_\'', '\'Enhertu_(Fam-Trastuzumab_Deruxtecan-nxki)_\'', '\'Etopophos_(Etoposide_Phosphate)_\'', '\'Exkivity_(Mobocertinib_Succinate)_\'', '\'Gavreto_(Pralsetinib)_\'', '\'Gemzar_(Gemcitabine_Hydrochloride)_\'', '\'Gilotrif_(Afatinib_Dimaleate)_\'', '\'Hycamtin_(Topotecan_Hydrochloride)_\'', '\'Imfinzi_(Durvalumab)_\'', '\'Imjudo_(Tremelimumab-actl)_\'', '\'Infugem_(Gemcitabine_Hydrochloride)_\'', '\'Iressa_(Gefitinib)_\'', '\'Keytruda_(Pembrolizumab)_\'', '\'Krazati_(Adagrasib)_\'', '\'Libtayo_(Cemiplimab-rwlc)_\'', '\'Lorbrena_(Lorlatinib)_\'',

'\'Lumakras_(Sotorasib)_\'', '\'Mekinist_(Trametinib_Dimethyl_Sulfoxide)_\'', '\'Mvasi_(Bevacizumab)_\'', '\'Opdivo_(Nivolumab)_\'', '\'Portrazza_(Necitumumab)_\'', '\'Retevmo_(Selpercatinib)_\'', '\'Rozlytrek_(Entrectinib)_\'', '\'Rybrevant_(Amivantamab-vmjw)_\'', '\'Tabrecta_(Capmatinib_Hydrochloride)_\'', '\'Tafinlar_(Dabrafenib_Mesylate)_\'', '\'Tagrisso_(Osimertinib_Mesylate)_\'', '\'Taxotere_(Docetaxel)_\'', '\'Tecentriq_(Atezolizumab)_\'', '\'Tepmetko_(Tepotinib_Hydrochloride)_\'', '\'Trexall_(Methotrexate_Sodium)_\'', '\'Vizimpro_(Dacomitinib)_\'', '\'Xalkori_(Crizotinib)_\'', '\'Yervoy_(Ipilimumab)_\'', '\'Zirabev_(Bevacizumab)_\'', '\'Zykadia_(Ceritinib)_\'', 4A_NSCLC, 4B_NSCLC, Adagrasib_, Adherence_Based_on_Socioeconomics_LC, Adherence_Factors_LC, Adverse_Reactions_ABRAX, Adverse_Reactions_ADAGR, Adverse_Reactions_AFATI, Adverse_Reactions_AFINI, Adverse_Reactions_AFINIT, Adverse_Reactions_ALECE, Adverse_Reactions_ALIMT, Adverse_Reactions_ALUNB, Adverse_Reactions_ALYMS, Adverse_Reactions_AMIVA, Adverse_Reactions_ATEZO, Adverse_Reactions_AVAST, Adverse_Reactions_BRIGA, Adverse_Reactions_CAPMA, Adverse_Reactions_CEMIP, Adverse_Reactions_CYRAM, Adverse_Reactions_DOXOR, Adverse_Reactions_DURVA, Adverse_Reactions_ENHER, Adverse_Reactions_ENTRE, Adverse_Reactions_ERLOT, Adverse_Reactions_ETOP, Adverse_Reactions_ETOPO, Adverse_Reactions_EXKIV, Adverse_Reactions_GAVRE, Adverse_Reactions_GEFIT, Adverse_Reactions_GEMZA, Adverse_Reactions_GILOT, Adverse_Reactions_HYCAM, Adverse_Reactions_IMFIN, Adverse_Reactions_IMJUD, Adverse_Reactions_INFUG, Adverse_Reactions_IRESS, Adverse_Reactions_KEYTR, Adverse_Reactions_KRAZA, Adverse_Reactions_LIBTA, Adverse_Reactions_LORBR, Adverse_Reactions_LUMAK, Adverse_Reactions_LURB, Adverse_Reactions_MEKIN, Adverse_Reactions_METH, Adverse_Reactions_MVASI, Adverse_Reactions_OPDIV, Adverse_Reactions_PORTR, Adverse_Reactions_RAMUC, Adverse_Reactions_RETEV, Adverse_Reactions_ROZLY, Adverse_Reactions_RYBRE, Adverse_Reactions_SELPE, Adverse_Reactions_SOTOR, Adverse_Reactions_TABRE, Adverse_Reactions_TAFIN, Adverse_Reactions_TAGRIS, Adverse_Reactions_TAXOT, Adverse_Reactions_TECEN, Adverse_Reactions_TEPME, Adverse_Reactions_TOPO, Adverse_Reactions_TRAME, Adverse_Reactions_TREME, Adverse_Reactions_TREXA, Adverse_Reactions_VINOR, Adverse_Reactions_VIZIM, Adverse_Reactions_XALKO, Adverse_Reactions_YERVO, Adverse_Reactions_ZIRAB, Adverse_Reactions_ZYKAD, Afatinib_Dimaleate_, Age, Air_Pollution, Amivantamab-vmjw_, Atezolizumab_, Behavioral_Factors_LC, Beta_Carotene_Supplements_LC, Bio_Sensors_LC, Biological_Effects_LC, Breathalyzer_LC, Breathing_LC, Brigatinib_, Capmatinib_Hydrochloride_, Causes_and_Risks_LC, Cemiplimab-rwlc_, Chemical_Sensors_LC, Choosing_Quality_of_Life_-_Reasons_People_Forego_Treatment, Choosing_Survival_-_Deciding_to_Undergo_Treatment, Clinical_Factors_LC, Complications_LC, Contraindications_ABRAX, Contraindications_ADAGR, Contraindications_AFATI, Contraindications_AFINI, Contraindications_AFINIT, Contraindications_ALECE, Contraindications_ALIMT, Contraindications_ALUNB, Contraindications_ALYMS, Contraindications_AMIVA, Contraindications_ATEZO, Contraindications_AVAST, Contraindications_BRIGA, Contraindications_CAPMA, Contraindications_CEMIP, Contraindications_CYRAM, Contraindications_DOXOR, Contraindications_DURVA, Contraindications_ENHER, Contraindications_ENTRE, Contraindications_ERLOT, Contraindications_ETOP, Contraindications_ETOPO, Contraindications_EXKIV, Contraindications_GAVRE, Contraindications_GEFIT, Contraindications_GEMZA, Contraindications_GILOT, Contraindications_HYCAM, Contraindications_IMFIN, Contraindications_IMJUD, Contraindications_INFUG, Contraindications_IRESS, Contraindications_KEYTR, Contraindications_KRAZA, Contraindications_LIBTA, Contraindications_LORBR, Contraindications_LUMAK, Contraindications_LURB, Contraindications_MEKIN, Contraindications_METH, Contraindications_MVASI, Contraindications_OPDIV, Contraindications_PORTR, Contraindications_RAMUC, Contraindications_RETEV, Contraindications_ROZLY, Contraindications_RYBRE, Contraindications_SELPE, Contraindications_SOTOR, Contraindications_TABRE, Contraindications_TAFIN, Contraindications_TAGRIS, Contraindications_TAXOT, Contraindications_TECEN, Contraindications_TEPME, Contraindications_TOPO, Contraindications_TRAME, Contraindications_TREME, Contraindications_TREXA, Contraindications_VINOR, Contraindications_VIZIM, Contraindications_XALKO, Contraindications_YERVO, Contraindications_ZIRAB, Contraindications_ZYKAD, Cultural_Beliefs_and_Perceptions, Cultural_LC, Degrees_of_Smoking_LC, Demographic_Factors_LC, Diet_LC, Disparities_in_Incidence, Dosage_and_Administration_ABRAX, Dosage_and_Administration_ADAGR, Dosage_and_Administration_AFATI, Dosage_and_Administration_AFINI, Dosage_and_Administration_AFINIT, Dosage_and_Administration_ALECE, Dosage_and_Administration_ALIMT, Dosage_and_Administration_ALUNB, Dosage_and_Administration_ALYMS, Dosage_and_Administration_AMIVA, Dosage_and_Administration_ATEZO, Dosage_and_Administration_AVAST, Dosage_and_Administration_BRIGA, Dosage_and_Administration_CAPMA, Dosage_and_Administration_CEMIP, Dosage_and_Administration_CYRAM, Dosage_and_Administration_DOXOR, Dosage_and_Administration_DURVA, Dosage_and_Administration_ENHER, Dosage_and_Administration_ENTRE, Dosage_and_Administration_ERLOT, Dosage_and_Administration_ETOP, Dosage_and_Administration_ETOPO, Dosage_and_Administration_EXKIV, Dosage_and_Administration_GAVRE, Dosage_and_Administration_GEFIT, Dosage_and_Administration_GEMZA, Dosage_and_Administration_GILOT, Dosage_and_Administration_HYCAM, Dosage_and_Administration_IMFIN, Dosage_and_Administration_IMJUD, Dosage_and_Administration_INFUG, Dosage_and_Administration_IRESS, Dosage_and_Administration_KEYTR, Dosage_and_Administration_KRAZA, Dosage_and_Administration_LIBTA, Dosage_and_Administration_LORBR, Dosage_and_Administration_LUMAK, Dosage_and_Administration_LURB, Dosage_and_Administration_MEKIN, Dosage_and_Administration_METH, Dosage_and_Administration_MVASI, Dosage_and_Administration_OPDIV, Dosage_and_Administration_PORTR, Dosage_and_Administration_RAMUC, Dosage_and_Administration_RETEV, Dosage_and_Administration_ROZLY, Dosage_and_Administration_RYBRE, Dosage_and_Administration_SELPE, Dosage_and_Administration_SOTOR, Dosage_and_Administration_TABRE,

Dosage_and_Administration_TAFIN, Dosage_and_Administration_TAGRIS, Dosage_and_Administration_TAXOT, Dosage_and_Administration_TECEN, Dosage_and_Administration_TEPME, Dosage_and_Administration_TOPO, Dosage_and_Administration_TRAME, Dosage_and_Administration_TREME, Dosage_and_Administration_TREXA, Dosage_and_Administration_VINOR, Dosage_and_Administration_VIZIM, Dosage_and_Administration_XALKO, Dosage_and_Administration_YERVO, Dosage_and_Administration_ZIRAB, Dosage_and_Administration_ZYKAD, Dosage_Forms_and_Strengths_ABRAX, Dosage_Forms_and_Strengths_ADAGR, Dosage_Forms_and_Strengths_AFATI, Dosage_Forms_and_Strengths_AFINI, Dosage_Forms_and_Strengths_AFINIT, Dosage_Forms_and_Strengths_ALECE, Dosage_Forms_and_Strengths_ALIMT, Dosage_Forms_and_Strengths_ALUNB, Dosage_Forms_and_Strengths_ALYMS, Dosage_Forms_and_Strengths_AMIVA, Dosage_Forms_and_Strengths_ATEZO, Dosage_Forms_and_Strengths_AVAST, Dosage_Forms_and_Strengths_BRIGA, Dosage_Forms_and_Strengths_CAPMA, Dosage_Forms_and_Strengths_CEMIP, Dosage_Forms_and_Strengths_CYRAM, Dosage_Forms_and_Strengths_DOXOR, Dosage_Forms_and_Strengths_DURVA, Dosage_Forms_and_Strengths_ENHER, Dosage_Forms_and_Strengths_ENTRE, Dosage_Forms_and_Strengths_ERLOT, Dosage_Forms_and_Strengths_ETOP, Dosage_Forms_and_Strengths_ETOPO, Dosage_Forms_and_Strengths_EXKIV, Dosage_Forms_and_Strengths_GAVRE, Dosage_Forms_and_Strengths_GEFIT, Dosage_Forms_and_Strengths_GEMZA, Dosage_Forms_and_Strengths_GILOT, Dosage_Forms_and_Strengths_HYCAM, Dosage_Forms_and_Strengths_IMFIN, Dosage_Forms_and_Strengths_IMJUD, Dosage_Forms_and_Strengths_INFUG, Dosage_Forms_and_Strengths_IRESS, Dosage_Forms_and_Strengths_KEYTR, Dosage_Forms_and_Strengths_KRAZA, Dosage_Forms_and_Strengths_LIBTA, Dosage_Forms_and_Strengths_LORBR, Dosage_Forms_and_Strengths_LUMAK, Dosage_Forms_and_Strengths_LURB, Dosage_Forms_and_Strengths_MEKIN, Dosage_Forms_and_Strengths_METH, Dosage_Forms_and_Strengths_MVASI, Dosage_Forms_and_Strengths_OPDIV, Dosage_Forms_and_Strengths_PORTR, Dosage_Forms_and_Strengths_RAMUC, Dosage_Forms_and_Strengths_RETEV, Dosage_Forms_and_Strengths_ROZLY, Dosage_Forms_and_Strengths_RYBRE, Dosage_Forms_and_Strengths_SELPE, Dosage_Forms_and_Strengths_SOTOR, Dosage_Forms_and_Strengths_TABRE, Dosage_Forms_and_Strengths_TAFIN, Dosage_Forms_and_Strengths_TAGRIS, Dosage_Forms_and_Strengths_TAXOT, Dosage_Forms_and_Strengths_TECEN, Dosage_Forms_and_Strengths_TEPME, Dosage_Forms_and_Strengths_TOPO, Dosage_Forms_and_Strengths_TRAME, Dosage_Forms_and_Strengths_TREME, Dosage_Forms_and_Strengths_TREXA, Dosage_Forms_and_Strengths_VINOR, Dosage_Forms_and_Strengths_VIZIM, Dosage_Forms_and_Strengths_XALKO, Dosage_Forms_and_Strengths_YERVO, Dosage_Forms_and_Strengths_ZIRAB, Dosage_Forms_and_Strengths_ZYKAD, Doxorubicin_Hydrochloride_, Drug_Interactions_ABRAX, Drug_Interactions_ADAGR, Drug_Interactions_AFATI, Drug_Interactions_AFINI, Drug_Interactions_AFINIT, Drug_Interactions_ALECE, Drug_Interactions_ALIMT, Drug_Interactions_ALUNB, Drug_Interactions_ALYMS, Drug_Interactions_AMIVA, Drug_Interactions_ATEZO, Drug_Interactions_AVAST, Drug_Interactions_BRIGA, Drug_Interactions_CAPMA, Drug_Interactions_CEMIP, Drug_Interactions_CYRAM, Drug_Interactions_DOXOR, Drug_Interactions_DURVA, Drug_Interactions_ENHER, Drug_Interactions_ENTRE, Drug_Interactions_ERLOT, Drug_Interactions_ETOP, Drug_Interactions_ETOPO, Drug_Interactions_EXKIV, Drug_Interactions_GAVRE, Drug_Interactions_GEFIT, Drug_Interactions_GEMZA, Drug_Interactions_GILOT, Drug_Interactions_HYCAM, Drug_Interactions_IMFIN, Drug_Interactions_IMJUD, Drug_Interactions_INFUG, Drug_Interactions_IRESS, Drug_Interactions_KEYTR, Drug_Interactions_KRAZA, Drug_Interactions_LIBTA, Drug_Interactions_LORBR, Drug_Interactions_LUMAK, Drug_Interactions_LURB, Drug_Interactions_MEKIN, Drug_Interactions_METH, Drug_Interactions_MVASI, Drug_Interactions_OPDIV, Drug_Interactions_PORTR, Drug_Interactions_RAMUC, Drug_Interactions_RETEV, Drug_Interactions_ROZLY, Drug_Interactions_RYBRE, Drug_Interactions_SELPE, Drug_Interactions_SOTOR, Drug_Interactions_TABRE, Drug_Interactions_TAFIN, Drug_Interactions_TAGRIS, Drug_Interactions_TAXOT, Drug_Interactions_TECEN, Drug_Interactions_TEPME, Drug_Interactions_TOPO, Drug_Interactions_TRAME, Drug_Interactions_TREME, Drug_Interactions_TREXA, Drug_Interactions_VINOR, Drug_Interactions_VIZIM, Drug_Interactions_XALKO, Drug_Interactions_YERVO, Drug_Interactions_ZIRAB, Drug_Interactions_ZYKAD, Durvalumab_, E-Cigarettes_LC, Electronic_Sensors_LC, Emotions_LC, End_of_Life_Decisions, Entrectinib_, Enzymatic_Sensors_LC, Erlotinib_Hydrochloride_, Etoposide_, Exercise_LC, Extensive_Stage_SCLC, Family_History_LC, Gefitinib_, Genomic_Sequencing_LC, **Geographical_Location**, Habits_LC, HIV_Infection_LC, Immunosensors_LC, Increased_Susceptibility_LC, Indications_and_Usage_ABRAX, Indications_and_Usage_ADAGR, Indications_and_Usage_AFATI, Indications_and_Usage_AFINI, Indications_and_Usage_AFINIT, Indications_and_Usage_ALECE, Indications_and_Usage_ALIMT, Indications_and_Usage_ALUNB, Indications_and_Usage_ALYMS, Indications_and_Usage_AMIVA, Indications_and_Usage_ATEZO, Indications_and_Usage_AVAST, Indications_and_Usage_BRIGA, Indications_and_Usage_CAPMA, Indications_and_Usage_CEMIP, Indications_and_Usage_CYRAM, Indications_and_Usage_DOXOR, Indications_and_Usage_DURVA, Indications_and_Usage_ENHER, Indications_and_Usage_ENTRE, Indications_and_Usage_ERLOT,

Indications_and_Usage_ETOP, Indications_and_Usage_ETOPO, Indications_and_Usage_EXKIV, Indications_and_Usage_GAVRE, Indications_and_Usage_GEFIT, Indications_and_Usage_GEMZA, Indications_and_Usage_GILOT, Indications_and_Usage_HYCAM, Indications_and_Usage_IMFIN, Indications_and_Usage_IMJUD, Indications_and_Usage_INFUG, Indications_and_Usage_IRESS, Indications_and_Usage_KEYTR, Indications_and_Usage_KRAZA, Indications_and_Usage_LIBTA, Indications_and_Usage_LORBR, Indications_and_Usage_LUMAK, Indications_and_Usage_LURB, Indications_and_Usage_MEKIN, Indications_and_Usage_METH, Indications_and_Usage_MVASI, Indications_and_Usage_OPDIV, Indications_and_Usage_PORTR, Indications_and_Usage_RAMUC, Indications_and_Usage_RETEV, Indications_and_Usage_ROZLY, Indications_and_Usage_RYBRE, Indications_and_Usage_SELPE, Indications_and_Usage_SOTOR, Indications_and_Usage_TABRE, Indications_and_Usage_TAFIN, Indications_and_Usage_TAGRIS, Indications_and_Usage_TAXOT, Indications_and_Usage_TECEN, Indications_and_Usage_TEPME, Indications_and_Usage_TOPO, Indications_and_Usage_TRAME, Indications_and_Usage_TREME, Indications_and_Usage_TREXA, Indications_and_Usage_VINOR, Indications_and_Usage_VIZIM, Indications_and_Usage_XALKO, Indications_and_Usage_YERVO, Indications_and_Usage_ZIRAB, Indications_and_Usage_ZYKAD, Limited_Stage_SCLC, Living_with_LC_LC, Lurbinectedin_, Marijuna_Smoking_LC, Medications_LC, Methotrexate_Sodium_, Never-Smokers_LC, Non-Small_Cell_LC, Non-Small_Cell_LC_NSCLC, Non-Small_Cell_Lung_Cancer, Non-Small_Cell_Medication_LC_, Non-Smokers_LC, Non-Smokers_NSCLC, Non-Smokers_SCLC, Nutrition_LC, Occupational_Exposure, Physical_Activity_For_Mitigation_of__LC, Physical_Activity_For_Prevention_Of_LC, Preventative_habits_LC, Quitting/Not_Smoking_LC, Racial/Ethnic, Radiation_Exposure_LC, Ramucirumab_, Recurring_LC_NSCLC, Recurring_LC_SCLC, Rural_LC, Second-hand_Smoke_LC, Secondhand_Smoke_LC, Selpercatinib_, Sensor_Factors_LC, Size_of_the_community_LC, Sleep_LC, Small_Cell_LC, Small_Cell_LC_SCLC, Small_Cell_Lung_Cancer, Small_Cell_Medication_LC_, Smoke_LC, Smokers_LC, Smokers_NSCLC, Smokers_SCLC, Smoking_LC, Smoking_Marijuana_LC, Smoking_Other_Drugs_LC, Smoking_Tobacco_LC, Socioeconomics_LC, Sotorasib_, Stage_0_NSCLC, Stage_1_NSCLC, Stage_1_SCLC, Stage_2_NSCLC, Stage_3A_NSCLC, Stage_3B_NSCLC, Stage_4_NSCLC, Support_Groups_LC, Symptoms_and_Tests_LC, Symptoms_NSC, Symptoms_SC, Tests_NSC, Tests_SC, Tobacco_Smoking, Tobacco_Smoking_LC, Topotecan_Hydrochloride_, Tramentinib_Dimethyl_Sulfoxide, Treatment_Regimens_LC, Treatments_LC, Tremelimumab-actl_, Urban_LC, Use_in_Specific_Populations_ABRAX, Use_in_Specific_Populations_ADAGR, Use_in_Specific_Populations_AFATI, Use_in_Specific_Populations_AFINI, Use_in_Specific_Populations_AFINIT, Use_in_Specific_Populations_ALECE, Use_in_Specific_Populations_ALIMT, Use_in_Specific_Populations_ALUNB, Use_in_Specific_Populations_ALYMS, Use_in_Specific_Populations_AMIVA, Use_in_Specific_Populations_ATEZO, Use_in_Specific_Populations_AVAST, Use_in_Specific_Populations_BRIGA, Use_in_Specific_Populations_CAPMA, Use_in_Specific_Populations_CEMIP, Use_in_Specific_Populations_CYRAM, Use_in_Specific_Populations_DOXOR, Use_in_Specific_Populations_DURVA, Use_in_Specific_Populations_ENHER, Use_in_Specific_Populations_ENTRE, Use_in_Specific_Populations_ERLOT, Use_in_Specific_Populations_ETOP, Use_in_Specific_Populations_ETOPO, Use_in_Specific_Populations_EXKIV, Use_in_Specific_Populations_GAVRE, Use_in_Specific_Populations_GEFIT, Use_in_Specific_Populations_GEMZA, Use_in_Specific_Populations_GILOT, Use_in_Specific_Populations_HYCAM, Use_in_Specific_Populations_IMFIN, Use_in_Specific_Populations_IMJUD, Use_in_Specific_Populations_INFUG, Use_in_Specific_Populations_IRESS, Use_in_Specific_Populations_KEYTR, Use_in_Specific_Populations_KRAZA, Use_in_Specific_Populations_LIBTA, Use_in_Specific_Populations_LORBR, Use_in_Specific_Populations_LUMAK, Use_in_Specific_Populations_LURB, Use_in_Specific_Populations_MEKIN, Use_in_Specific_Populations_METH, Use_in_Specific_Populations_MVASI, Use_in_Specific_Populations_OPDIV, Use_in_Specific_Populations_PORTR, Use_in_Specific_Populations_RAMUC, Use_in_Specific_Populations_RETEV, Use_in_Specific_Populations_ROZLY, Use_in_Specific_Populations_RYBRE, Use_in_Specific_Populations_SELPE, Use_in_Specific_Populations_SOTOR, Use_in_Specific_Populations_TABRE, Use_in_Specific_Populations_TAFIN, Use_in_Specific_Populations_TAGRIS, Use_in_Specific_Populations_TAXOT, Use_in_Specific_Populations_TECEN, Use_in_Specific_Populations_TEPME, Use_in_Specific_Populations_TOPO, Use_in_Specific_Populations_TRAME, Use_in_Specific_Populations_TREME, Use_in_Specific_Populations_TREXA, Use_in_Specific_Populations_VINOR, Use_in_Specific_Populations_VIZIM, Use_in_Specific_Populations_XALKO, Use_in_Specific_Populations_YERVO, Use_in_Specific_Populations_ZIRAB, Use_in_Specific_Populations_ZYKAD, Vinorelbine_Tartrate_, Warnings_and_Precautions_ABRAX, Warnings_and_Precautions_ADAGR, Warnings_and_Precautions_AFATI, Warnings_and_Precautions_AFINI, Warnings_and_Precautions_AFINIT, Warnings_and_Precautions_ALECE, Warnings_and_Precautions_ALIMT, Warnings_and_Precautions_ALUNB, Warnings_and_Precautions_ALYMS, Warnings_and_Precautions_AMIVA, Warnings_and_Precautions_ATEZO, Warnings_and_Precautions_AVAST, Warnings_and_Precautions_BRIGA, Warnings_and_Precautions_CAPMA, Warnings_and_Precautions_CEMIP, Warnings_and_Precautions_CYRAM, Warnings_and_Precautions_DOXOR, Warnings_and_Precautions_DURVA, Warnings_and_Precautions_ENHER, Warnings_and_Precautions_ENTRE, Warnings_and_Precautions_ERLOT, Warnings_and_Precautions_ETOP, Warnings_and_Precautions_ETOPO, Warnings_and_Precautions_EXKIV, Warnings_and_Precautions_GAVRE, Warnings_and_Precautions_GEFIT, Warnings_and_Precautions_GEMZA, Warnings_and_Precautions_GILOT, Warnings_and_Precautions_HYCAM, Warnings_and_Precautions_IMFIN, Warnings_and_Precautions_IMJUD, Warnings_and_Precautions_INFUG, Warnings_and_Precautions_IRESS, Warnings_and_Precautions_KEYTR, Warnings_and_Precautions_KRAZA, Warnings_and_Precautions_LIBTA, Warnings_and_Precautions_LORBR, Warnings_and_Precautions_LUMAK,

Warnings_and_Precautions_LURB, Warnings_and_Precautions_MEKIN, Warnings_and_Precautions_METH, Warnings_and_Precautions_MVASI, Warnings_and_Precautions_OPDIV, Warnings_and_Precautions_PORTR, Warnings_and_Precautions_RAMUC, Warnings_and_Precautions_RETEV, Warnings_and_Precautions_ROZLY, Warnings_and_Precautions_RYBRE, Warnings_and_Precautions_SELPE, Warnings_and_Precautions_SOTOR, Warnings_and_Precautions_TABRE, Warnings_and_Precautions_TAFIN, Warnings_and_Precautions_TAGRIS, Warnings_and_Precautions_TAXOT, Warnings_and_Precautions_TECEN, Warnings_and_Precautions_TEPME, Warnings_and_Precautions_TOPO, Warnings_and_Precautions_TRAME, Warnings_and_Precautions_TREME, Warnings_and_Precautions_TREXA, Warnings_and_Precautions_VINOR, Warnings_and_Precautions_VIZIM, Warnings_and_Precautions_XALKO, Warnings_and_Precautions_YERVO, Warnings_and_Precautions_ZIRAB, Warnings_and_Precautions_ZYKAD

OWL HTML inside